30 Nov 2022 07:00
30 November 2022
N4 Pharma plc
("N4 Pharma" or the "Company")
Total Voting Rights
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 233,780,349 ordinary shares of 0.4 pence each ("Ordinary Shares").
The total issued share capital of the Company consists of 233,780,349 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury. Therefore, the total current voting rights in the Company is 233,780,349 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
N4 Pharma plc |
|
Nigel Theobald, CEO | Via IFC Advisory |
Luke Cairns, Executive Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Joint Broker | |
Matthew Johnson/Caroline Rowe (Corporate Finance) | |
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | |
|
|
Turner Pope Investments (TPI) Limited | Tel: +44(0)20 3657 0050 |
Joint Broker | |
Andy Thacker James Pope | |
| |
IFC Advisory Ltd | Tel: +44(0)20 3934 6630 |
Financial PR | |
Graham Herring | |
Zach Cohen | |
|
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
N4 Pharma Plc (N4P)